Trial Profile

A pivotal XmAb 541 in Advanced Solid Tumors

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 20 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs XmAb 541 (Primary)
Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Uterine cancer
Focus Therapeutic Use

Most Recent Events

20 Jan 2026 New trial record
08 Jan 2026 According to a Xencor media release, the company to initiate this pivotal study in 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com